ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Mark Schneyer Sells 3,506 Shares of Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Mark Schneyer sold 3,506 shares of ACADIA Pharmaceuticals stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $21.79, for a total value of $76,395.74. Following the completion of the sale, the executive vice president owned 66,145 shares in the company, valued at approximately $1,441,299.55. The trade was a 5.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

ACADIA Pharmaceuticals Stock Performance

NASDAQ ACAD opened at $22.35 on Wednesday. The stock’s fifty day moving average is $22.16 and its two-hundred day moving average is $23.88. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $14.45 and a fifty-two week high of $28.35. The firm has a market capitalization of $3.83 billion, a P/E ratio of 9.76, a price-to-earnings-growth ratio of 23.15 and a beta of 0.86.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $1.48. The firm had revenue of $298.00 million for the quarter, compared to the consensus estimate of $292.54 million. ACADIA Pharmaceuticals had a return on equity of 12.49% and a net margin of 36.49%.The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.86 EPS. As a group, sell-side analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.45 EPS for the current year.

Institutional Trading of ACADIA Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Farther Finance Advisors LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 67.5% in the fourth quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 386 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in ACADIA Pharmaceuticals in the 4th quarter worth about $26,000. Geneos Wealth Management Inc. lifted its position in shares of ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 756 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of ACADIA Pharmaceuticals by 107.0% during the third quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 885 shares in the last quarter. Finally, Transamerica Financial Advisors LLC increased its holdings in shares of ACADIA Pharmaceuticals by 304.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 1,005 shares during the period. Institutional investors own 96.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ACAD shares. UBS Group increased their price target on ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Citigroup raised their target price on shares of ACADIA Pharmaceuticals from $33.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Citizens Jmp increased their price objective on ACADIA Pharmaceuticals from $34.00 to $35.00 and gave the company a “market outperform” rating in a research note on Thursday, February 26th. Royal Bank Of Canada decreased their price objective on ACADIA Pharmaceuticals from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Thursday, February 26th. Finally, Wall Street Zen downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.21.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.